North America is accounted for the high prevalence of skin disease especially acne. Due to this factor, the region is expected to hold the dominant position in the global acne vulgaris treatment market. According to the American Medical Association, ACNE affects between 40 million and 50 million individuals in the United States. Although acne mainly affects adolescents, it is also present in children and adults. One study found some degree of facial acne in 54% of women and 40% of men older than 25 years.
Growing awareness regarding acne in teenagers coupled with the rise in disposable income is augmenting the growth of the acne vulgaris treatment market. Manufacturers are focussing on introducing effective treatments for acne vulgaris which is also uplifting the growth of the market. In September 2020, Alembic Pharmaceuticals announces the launch of their bioequivalent and therapeutically equivalent product to Differin Gel 0.3% (Galderma), Adapalene Gel USP 0.3%, a topical retinoid for the treatment of acne vulgaris in patients 12 years and older. Also, in August 2020, the U.S. Food and Drug Administration (FDA) approved Italy-based Cassiopea SpA’s acne treatment Winlevi (clascoterone cream 1%). Winlevi is the first acne drug with a new mechanism of action to win regulatory approval in the United States.
In December 2019, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, the prescription dermatology health care businesses announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for ARAZLOTM (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older.
In August 2020, Cassiopea SpA announced that the United States Food and Drug Administration (FDA) approved Winlevi® (clascoterone cream 1%) for the treatment of acne in patients 12 years and older
In December 2020, Sol-Gel Technologies, Ltd. launched New Drug Application (NDA) for Twyneo® (benzoyl peroxide and tretinoin), an investigational proprietary fixed-dose combination of 3% encapsulated benzoyl peroxide and 0.1% encapsulated tretinoin cream for the treatment of acne vulgaris
Acne vulgaris treatment is vital to keep skin clear and healthy. This type of acne affects almost everyone at some point in their life. Acne vulgaris treatment is also essential because of the long-term health effects that can result from this type of skin disease. Acne vulgaris is a serious skin disease that happens when oil and dead skin cells from skin clog pores and cause inflammation. Common symptoms of this condition include whiteheads or blackheads, inflamed skin, acne scars, acne, and possible scarring to face.
In August 2020, Cassiopea SpA announced that the United States Food and Drug Administration (FDA) approved Winlevi® (clascoterone cream 1%) for the treatment of acne in patients 12 years and older
In December 2020, Sol-Gel Technologies, Ltd. launched New Drug Application (NDA) for Twyneo® (benzoyl peroxide and tretinoin), an investigational proprietary fixed-dose combination of 3% encapsulated benzoyl peroxide and 0.1% encapsulated tretinoin cream for the treatment of acne vulgaris
Acne vulgaris treatment is vital to keep skin clear and healthy. This type of acne affects almost everyone at some point in their life. Acne vulgaris treatment is also essential because of the long-term health effects that can result from this type of skin disease. Acne vulgaris is a serious skin disease that happens when oil and dead skin cells from skin clog pores and cause inflammation. Common symptoms of this condition include whiteheads or blackheads, inflamed skin, acne scars, acne, and possible scarring to face.
No comments:
Post a Comment